ISA to Present Results of Randomized Phase II Study of ISA101b in Head and Neck Cancer at the ASCO Annual Meeting 2024

ISA reports highlights of randomized Phase 2 cancer vaccine trial in head & neck cancer

ISA Pharmaceuticals to Attend and Present at Upcoming Scientific and Business Conferences

Professor Melief to receive 2022 SITC Pedro J. Romero Award

ISA Pharmaceuticals Receives Fast Track Designation for Lead Product ISA101b

ISA announces successful closing of EUR 26 million funding round

First Patient Treated in Phase II Combination Trial of ISA Pharmaceuticals’ Lead Immunotherapy ISA101b with Keytruda®

ISA Pharmaceuticals to present at the 33rd International Papillomavirus Conference & Basic Science

ISA Pharmaceuticals receives US Orphan-Drug Designation for ISA101b in HPV16-positive Cervical Cancer

ISA Pharmaceuticals to present at the Virtual European Biotech Investor Day 2020